JP2005523687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523687A5 JP2005523687A5 JP2003557507A JP2003557507A JP2005523687A5 JP 2005523687 A5 JP2005523687 A5 JP 2005523687A5 JP 2003557507 A JP2003557507 A JP 2003557507A JP 2003557507 A JP2003557507 A JP 2003557507A JP 2005523687 A5 JP2005523687 A5 JP 2005523687A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- tm7xn1
- moiety
- compound
- astrocytoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 29
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 claims 9
- 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 claims 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010003571 Astrocytoma Diseases 0.000 claims 6
- 238000003384 imaging method Methods 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 231100000196 chemotoxic Toxicity 0.000 claims 1
- 230000002604 chemotoxic effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000011820 transgenic animal model Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
- 239000012905 visible particle Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34342201P | 2001-12-27 | 2001-12-27 | |
| PCT/US2002/041419 WO2003057148A2 (en) | 2001-12-27 | 2002-12-23 | Use of biomolecular targets in the treatment and visualization of tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523687A JP2005523687A (ja) | 2005-08-11 |
| JP2005523687A5 true JP2005523687A5 (https=) | 2005-12-22 |
Family
ID=23346050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003557507A Pending JP2005523687A (ja) | 2001-12-27 | 2002-12-23 | 腫瘍の処置及び可視化における生体分子標的の使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7014838B2 (https=) |
| EP (1) | EP1465997A4 (https=) |
| JP (1) | JP2005523687A (https=) |
| AU (1) | AU2002360773A1 (https=) |
| CA (1) | CA2469480A1 (https=) |
| WO (1) | WO2003057148A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005073621A (ja) * | 2003-09-01 | 2005-03-24 | Japan Science & Technology Agency | 脳腫瘍マーカーと脳腫瘍の診断方法 |
| US20050255045A1 (en) * | 2004-05-13 | 2005-11-17 | Woltering Eugene A | Surgical marking composition and method |
| EP2290073A3 (en) * | 2004-05-28 | 2011-08-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| WO2006020557A2 (en) * | 2004-08-10 | 2006-02-23 | Immusol, Inc. | Methods of using or identifying agents that inhibit cancer growth |
| EP2302055B1 (en) | 2004-11-12 | 2014-08-27 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| US20090081221A1 (en) * | 2004-11-15 | 2009-03-26 | Kirin Beer Kabushiki Kaisha | Method for suppressing cancer cell metastasis and pharmaceutical composition for use in the method |
| US9603941B2 (en) * | 2006-01-24 | 2017-03-28 | Minghui Chai | Method of preparing dendritic drugs |
| US20090131348A1 (en) * | 2006-09-19 | 2009-05-21 | Emmanuel Labourier | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| WO2008036776A2 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
| AU2007333109A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro RNAs |
| AU2007333107A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
| WO2008073915A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
| CA2671270A1 (en) * | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
| US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| US20090232893A1 (en) * | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| AU2008261951A1 (en) * | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | miR-34 regulated genes and pathways as targets for therapeutic intervention |
| WO2009036332A1 (en) | 2007-09-14 | 2009-03-19 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
| WO2009052386A1 (en) * | 2007-10-18 | 2009-04-23 | Asuragen, Inc. | Micrornas differentially expressed in lung diseases and uses thereof |
| WO2009070805A2 (en) * | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
| WO2009086156A2 (en) * | 2007-12-21 | 2009-07-09 | Asuragen, Inc. | Mir-10 regulated genes and pathways as targets for therapeutic intervention |
| EP2260110B1 (en) * | 2008-02-08 | 2014-11-12 | Asuragen, INC. | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
| WO2009111643A2 (en) * | 2008-03-06 | 2009-09-11 | Asuragen, Inc. | Microrna markers for recurrence of colorectal cancer |
| EP2271757A2 (en) * | 2008-03-26 | 2011-01-12 | Asuragen, INC. | Compositions and methods related to mir-16 and therapy of prostate cancer |
| WO2009137807A2 (en) | 2008-05-08 | 2009-11-12 | Asuragen, Inc. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
| CA2738124A1 (en) * | 2008-09-22 | 2010-03-25 | Nihon Medi-Physics Co., Ltd. | Device for creating database of alternative normal brain |
| US20100074480A1 (en) | 2008-09-22 | 2010-03-25 | University Of Washington | Device for generating alternative of normal brain database |
| WO2010056737A2 (en) * | 2008-11-11 | 2010-05-20 | Mirna Therapeutics, Inc. | Methods and compositions involving mirnas in cancer stem cells |
| JP2014506789A (ja) | 2011-02-03 | 2014-03-20 | マーナ セラピューティクス インコーポレイテッド | ｍｉＲ−１２４の合成模倣体 |
| WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
| US20170065691A1 (en) * | 2014-03-20 | 2017-03-09 | University Of Southern California | Brain cancer immunotherapy |
| WO2017172945A1 (en) * | 2016-03-31 | 2017-10-05 | Children's Medical Center Corporation | Compositions and methods for oligodendrocyte development |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030167485A1 (en) * | 1997-09-24 | 2003-09-04 | Garvan Institute Of Medical Research | Novel G protein-coupled receptor encoding gene and diagnostic uses therefor |
| US6391311B1 (en) * | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| WO2000020590A2 (en) * | 1998-10-06 | 2000-04-13 | Incyte Pharmaceuticals, Inc. | G-protein coupled receptor proteins |
| EP1033404A1 (en) * | 1999-01-29 | 2000-09-06 | F. Hoffmann-La Roche Ag | New gene with down-regulated expression in metastatic human melanoma cells |
-
2002
- 2002-12-23 JP JP2003557507A patent/JP2005523687A/ja active Pending
- 2002-12-23 US US10/329,258 patent/US7014838B2/en not_active Expired - Lifetime
- 2002-12-23 AU AU2002360773A patent/AU2002360773A1/en not_active Abandoned
- 2002-12-23 US US10/328,544 patent/US7368098B2/en not_active Expired - Lifetime
- 2002-12-23 WO PCT/US2002/041419 patent/WO2003057148A2/en not_active Ceased
- 2002-12-23 EP EP02796055A patent/EP1465997A4/en not_active Withdrawn
- 2002-12-23 CA CA002469480A patent/CA2469480A1/en not_active Abandoned
-
2008
- 2008-03-10 US US12/045,448 patent/US20080226646A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523687A5 (https=) | ||
| JP2025041675A (ja) | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 | |
| Li et al. | Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas | |
| CN101555283B (zh) | 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途 | |
| Spitzweg et al. | The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment | |
| Westberg et al. | Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma | |
| Jia et al. | Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer | |
| Vandergrift et al. | Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas | |
| Dorst et al. | Targeted photodynamic therapy selectively kills activated fibroblasts in experimental arthritis | |
| JP2014504149A (ja) | 治療と併用する癌画像診断：セラノスティックス | |
| Shih et al. | 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma | |
| Achmad et al. | Predicting cetuximab accumulation in KRAS wild‐type and KRAS mutant colorectal cancer using 64Cu‐labeled cetuximab positron emission tomography | |
| Finn et al. | Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas | |
| Petronzelli et al. | Therapeutic use of avidin is not hampered by antiavidin antibodies in humans | |
| You et al. | Molecular magnetic resonance probe targeting VEGF165: preparation and in vitro and in vivo evaluation | |
| Beresford et al. | Binding characteristics and tumor targeting of a covalently linked divalent CC49 single‐chain antibody | |
| CN111615518B (zh) | 阻断emt途径并克服癌干细胞的il8 | |
| Taha et al. | Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy | |
| Simons et al. | PSMA expression in the Hi‐Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool | |
| JP2001513111A (ja) | 腫瘍付随血管（ｔｕｍｏｒ−ａｓｓｏｃｉａｔｅｄ ｂｌｏｏｄ ｖｅｓｓｅｌｓ）上の血管透過因子の複数のエピトープに結合する同時インビボイムノコンジュゲート | |
| Li et al. | Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo | |
| De Bonis et al. | Radioimmunotherapy for high-grade glioma | |
| Apparailly et al. | Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis | |
| JP2004537282A5 (https=) | ||
| KR102018774B1 (ko) | Glypican-3에 선택적으로 결합하는 압타머 및 이의 용도 |